Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

  1. Motzer, R.J.
  2. Choueiri, T.K.
  3. Hutson, T.
  4. Young Rha, S.
  5. Puente, J.
  6. Lalani, A.-K.A.
  7. Winquist, E.
  8. Eto, M.
  9. Basappa, N.S.
  10. Tannir, N.M.
  11. Vaishampayan, U.
  12. Bjarnason, G.A.
  13. Oudard, S.
  14. Grünwald, V.
  15. Burgents, J.
  16. Xie, R.
  17. McKenzie, J.
  18. Powles, T.
Aldizkaria:
European Urology

ISSN: 1873-7560,  0302-2838

Argitalpen urtea: 2024

Alea: 86

Zenbakia: 1

Orrialdeak: 4-9

Mota: Artikulua

DOI: 10.1016/J.EURURO.2024.03.015 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus